I-Mab, a global biotech company, has announced positive results from a Phase 1b dose escalation study of their novel drug, givastomig, combined with immunochemotherapy in patients with first-line gastric cancers. The study reported a 71% objective response rate $(ORR.AU)$ among participants, with an 83% ORR in patients across doses selected for an ongoing dose expansion study. The trial, which enrolled patients in the U.S., focused on evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of givastomig in combination with nivolumab and mFOLFOX6. The primary endpoint of safety showed no dose limiting toxicities, and a maximum tolerated dose was not reached. Common treatment-related adverse events were generally mild to moderate. These findings are set to be presented at the ESMO Gastrointestinal Cancers Congress 2025 on July 2nd. I-Mab has scheduled an investor event on July 8th to further discuss the results.